The Centers for Disease Control and Prevention reported that during July and August 2025 roughly one in 10 U.S. adults said they had taken a GLP-1 medication in the previous year. The statistic comes directly from the CDC report cited in the source. This level of self-reported use indicates a substantial penetration of these agents into the adult population over a relatively short period. The article did not provide granular demographic breakdowns or the survey’s sampling frame beyond the CDC citation, so the reader should consult the original CDC report for those methodological details.
Among respondents who reported taking a GLP-1, investigators observed that about one in five reported using a compounded version. Additionally, roughly 9% of GLP-1 users said they were uncertain whether their medication was compounded, a finding that signals practical difficulties distinguishing compounded products from medicines approved by the U.S. Food and Drug Administration. The data indicated that approximately two in five GLP-1 users modified their medication use from how it was prescribed. Cost and availability were cited by the cohort as reasons for those changes.
These behaviors carry several clinical and regulatory implications. Compounded preparations vary in formulation and oversight compared with FDA-approved products. Altered dosing or schedules, particularly when driven by affordability or supply constraints, can affect therapeutic outcomes and adverse event profiles. The STAT item did not report specifics such as which GLP-1 agents were most commonly used, precise rates of particular modifications, or clinical outcomes linked to these patterns; that information would require reviewing the CDC report or subsequent studies.
Industry trade representatives, via the International Federation of Pharmaceutical Manufacturers, are pushing for an audit by one of the Big 4 accounting firms of private contributions to the World Health Organization’s Pandemic Influenza Preparedness Framework. The group is seeking greater visibility into how millions of dollars contributed by drugmakers are being spent to prepare for the next influenza pandemic. The source reported that some manufacturers have temporarily withheld funds while pressing for that outside review.
The WHO’s response, as reported in the source, is that it already engages an external auditor and that it spends funds in accordance with its rules. The STAT excerpt did not include documentary evidence of the audit request, detailed accounting figures, or comments from specific manufacturers beyond the trade association’s position. Readers seeking full documentation or a line-by-line account of expenditures should consult the original reporting cited by the STAT piece or statements issued by the WHO and the International Federation of Pharmaceutical Manufacturers.
The article included an item headlined that Russia may seize intellectual property rights of foreign drugmakers leaving the country. The source provided that headline but did not supply expanded details in the excerpt about which laws would be invoked, which firms could be affected, or whether any formal government action had been taken. No additional legal analysis or named corporate cases appeared in the available text.
Limitations and paywall note
The STAT article is labeled as exclusive content for STAT+ subscribers. The publicly available excerpt summarized the CDC findings and the industry-WHO dispute, but it did not print the full reporting or any extended interviews, company-level responses, or deeper data tables that may appear behind the STAT+ paywall. The piece also did not report demographic stratification of GLP-1 use, specific clinical outcomes tied to altered dosing, or granular accounting entries for WHO program spending. Those details would require access to the full STAT+ article or to the primary source documents cited by the STAT reporting.
Unanswered questions from the available text
The reporting presented here is confined to the facts published in the STAT excerpt and the CDC citation it referenced. For operational or clinical decisions, consult the CDC report and primary policy statements from the WHO and industry groups.